At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 3, 2026 at 06:45 ET
BioNTech reported Q3 2026 revenue of €1,289.2M, beating the €1,040M consensus, and GAAP diluted EPS of €0.73, slightly below the $0.76 consensus. The company raised its full-year 2026 revenue guidance midpoint to €1.7-1.9 billion from €1.6-1.9 billion, driven by COVID-19 vaccine sales, while maintaining its oncology pipeline investments.
- Q3 2026 revenue €1,289.2M vs consensus €1,040M (beat)
- GAAP diluted EPS €0.73 vs consensus $0.76 (miss by ~4%)
- Full-year 2026 revenue guidance raised to €1.7-1.9 billion from €1.6-1.9 billion
- Adjusted R&D expenses €578.5M, within unchanged guidance of €2.0-2.3 billion
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access